A Phase III Randomized Trial Investigating Bortezomib (NSC 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Latest Information Update: 06 Feb 2025
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Folinic acid; Folinic acid; Hydrocortisone; Ifosfamide; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Pegaspargase; Tioguanine; Vincristine
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
Most Recent Events
- 13 Nov 2024 Planned End Date changed from 22 Sep 2024 to 18 Sep 2025.
- 12 Dec 2023 Results from AALL0434 and AALL1231 , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 26 Sep 2023 Planned End Date changed from 22 Sep 2023 to 22 Sep 2024.